|
Progression and hyperprogression after anti-PD1 therapy for unresectable stage III or IV melanoma patients. |
|
|
Honoraria - Servier/Pfizer |
|
|
|
Stock and Other Ownership Interests - Sanofi (I) |
Research Funding - BMS Brazil (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - BMS Brazil |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - BMS Brazil; MSD; Novartis; Pierre Fabre; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - BMS Brazil; Janssen; MSD |
|
|
Consulting or Advisory Role - BMS Brazil; MSD; Pierre Fabre |
Research Funding - BMS Brazil (Inst); Leo Pharma (Inst) |
Travel, Accommodations, Expenses - BMS Brazil; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Array BioPharma; BMS Brazil; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi |
Consulting or Advisory Role - Array BioPharma; BMS Brazil; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi |
|
Travel, Accommodations, Expenses - BMS Brazil; MSD; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Incyte; MSD; Novartis; Pfizer; Pierre Fabre; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Novartis; Roche |
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
Other Relationship - Avantis Medical Systems |